Dosing Starts in Phase 2/3 Trial of Athira’s ATH-1017 for Alzheimer’s

Dosing Starts in Phase 2/3 Trial of Athira’s ATH-1017 for Alzheimer’s
Dosing of patients has begun in a Phase 2/3 clinical trial evaluating ATH-1017, Athira Pharma's investigational candidate for the treatment of mild to moderate Alzheimer’s disease. “Embarking on this trial to evaluate our new approach to treating Alzheimer’s is the start of a collective experience that will involve not only individuals with Alzheimer’s but their caregivers and family members,” Leen Kawas, PhD, president and CEO of Athira, said in a press release. Called LIFT-AD, the randomized trial (NCT04488419) will evaluate the safety and efficacy of ATH-1017 (previously known as NDX-1017), compared with a placebo, for the treatment of mild to moderate Alzheimer’s disease. An estimated 300 individuals are currently being recruited for the trial in Florida and Washington; more information can be found here. Participants will be randomly assigned to receive either a low or high dose of ATH-1017 or a placebo, delivered subcutaneously (under the skin) daily for 26 weeks. Clinical efficacy will be demonstrated by improvement in cognition and functional assessments compared with the placebo. Secondary objectives include assessing ATH-1017's effects on cognition as measured by
Subscribe or to access all post and page content.